Topics:
ARS 2014|Breast Cancer|Colorectal Cancer|Leukemia & Lymphoma|Lung Cancer|Melanoma|ASCO 2014|Prostate Cancer|Browse All Topics

Breast Cancer

Management of Young Breast Cancer Patients With de Novo Genetic Mutations

A 24-year-old woman presents to her primary care provider with a mass in her left breast. Examination confirms a 2.2-cm mass in the upper outer quadrant, with a single mobile axillary node that is firm to palpation.

Breast Cancer

Adoption of Hypofractionated Radiotherapy in Early-Stage Breast Cancer

Aaron Falchook, MD
Blog | January 28, 2015 | Breast Cancer, Radiation Oncology
By

The benefit of hypofractionated radiotherapy for women receiving breast-conserving therapy for early-stage breast cancer is becoming more apparent.

MBI Boosts Cancer Detection in Patients With Dense Breasts

Anna Azvolinsky, PhD
News | January 27, 2015 | Breast Cancer
By

Adding molecular breast imaging to mammography resulted in a fourfold increase in invasive breast cancer detection rates in women with dense breasts.

Breast Cancer Patients Often Don't Know Details of Their Tumor

Janet Colwell
News | January 27, 2015 | Oncology Nursing, Breast Cancer
By

Many women with breast cancer do not understand the details of their tumor characteristics or how they relate to specific treatment options, according to a new study.

Benign Breast Mass Not So Benign After All

OBGYN.net Staff
January 16, 2015 | Breast Cancer
By

New evidence reveals that risk prediction for breast cancer is imperative in women with atypical hyperplasia of breast tissue.

The Role of Bisphosphonates in Early- and Advanced-Stage Breast Cancer: Have We Finally Optimized Care?

Phillip S. Blanchette, MSc, MD
Kathleen I. Pritchard, MD, FRCPC
Review Article | January 15, 2015 | Oncology Journal, Breast Cancer
By and

Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia.

Bisphosphonates: Game Changers?

I. Craig Henderson, MD, FACP, FRCP
Editorial | January 15, 2015 | Oncology Journal, Breast Cancer
By

Bisphosphonates or the monoclonal antibody denosumab, have the potential to profoundly affect the entire metastatic process, not just the growth of bone metastases.

Osteoclast Inhibitors: A Multifaceted Tool in the Management of Breast Cancer

Aki Morikawa MD, PhD
Catherine Van Poznak, MD
January 15, 2015 | Oncology Journal, Breast Cancer
By and

There are still questions to be answered about the use of osteoclast inhibitors in the care of patients with breast cancer. The optimal duration and dosing schedule and how to improve treatment compliance are important issues to address.

Pages

Subscribe to Breast Cancer on [sitename]
View More Videos
View More Podcasts

By clicking Accept, you agree to become a member of the UBM Medica Community.